FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2065564927> ?p ?o ?g. }

• W2065564927 abstract "Proceedings: AACR 104th Annual Meeting 2013; Apr 6-10, 2013; Washington, DCBackground: Epidermal growth factor receptor (EGFR) inhibition in TNBC has shown promising response in some studies, however, these studies have not investigated the correlation between response to EGFR inhibition and EGFR-related biomarker status. In this study, EGFR-related biomarkers in TNBC including p53 expression, EGFR gene amplification, and signalling pathways including RAS and PI3K were investigated to explore potential biomarkers that may correlate with response to EGFR inhibition.Methods: A total of 71 locally advanced or metastatic TNBC patients with no prior EGFR inhibitor treatment and 0 - 1 prior chemotherapy regimens for metastatic breast cancer were evaluated. All patients received gemcitabine 1500mg/m2 IV, carboplatin AUC = 2.5 IV, and panitumumab 6 mg/kg IV every 2 weeks. Archival tumor tissue was obtained from 68 patients for central biomarker analyses. Protein expression of PTEN and p53 in tumor samples was assessed by Immunohistochemistry (IHC). Fluorescence-in-situ-hybridization (FISH) was used to detect EGFR gene amplification. KRAS (codons 12 and 13 in exon 2) and PI3KCA (exons 9 and 20) mutations were analyzed by direct DNA sequencing using capillary gel electrophoresis and fluorescence detection. Bioinformatics analyses were performed to correlate the status of these biomarkers with objective response rate (ORR), progression free survival (PFS) and overall survival (OS).Results: 27 patients had partial response (PR), median PFS was 4.30 months and median OS was 12.58 months. 12/68 (18%) tumors had EGFR amplification. No KRAS mutations were detected in the 62 samples tested (6 patients not evaluable). 18% of tumors demonstrated PI3KCA mutations (12/67). 5/67 (7%) samples had PTEN loss. 50% of the tumors exhibited p53 loss (34/68). 13/68 (19%) tumors had more than one biomarker alteration. PTEN loss and PI3KCA mutation were mutually exclusive in the 67 tumors evaluated. In univariate analyses, none of these biomarkers significantly correlated with ORR, PFS or OS (all, P>0.05). There was a marginal trend to shorter PFS (P=0.08) with PTEN loss and a marginal trend to longer PFS (P=0.106) with p53 loss. In multivariate analyses, none of the four biomarkers (EGFR, PI3KCA, PTEN and p53) showed prognostic significance on OS (all, P>0.05).Conclusions: We hypothesize that constitutive activation of the PI3K pathway due to PTEN loss and activation of EGFR by p53 loss may be potential mechanisms for the observed responses to panitumumab. This single arm study suggests that EGFR gene amplification may not be a predictor for response to panitumumab in TNBC. Further investigation in a randomized trial with a more homogenous patient population is warranted to confirm these findings.Citation Format: Denise Yardley, Denise Yardley, Zeqiang Ma, Patrick Ward, Carolyn Hendricks, Brooke Daniel, William Harwin, George J. Kannarkat, Mythili Shastry, Nancy Peacock, Shile Liang. Correlation between biomarker status and response to EGFR inhibition in triple-negative breast cancer (TNBC): findings from a Phase II trial. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 2397. doi:10.1158/1538-7445.AM2013-2397" @default.
• W2065564927 created "2016-06-24" @default.
• W2065564927 creator A5011626141 @default.
• W2065564927 creator A5022422153 @default.
• W2065564927 creator A5037872546 @default.
• W2065564927 creator A5053655884 @default.
• W2065564927 creator A5056663291 @default.
• W2065564927 creator A5062084998 @default.
• W2065564927 creator A5062468425 @default.
• W2065564927 creator A5068246195 @default.
• W2065564927 creator A5069803966 @default.
• W2065564927 creator A5088419677 @default.
• W2065564927 date "2013-04-15" @default.
• W2065564927 modified "2023-09-27" @default.
• W2065564927 title "Abstract 2397: Correlation between biomarker status and response to EGFR inhibition in triple-negative breast cancer (TNBC): findings from a Phase II trial." @default.
• W2065564927 doi "https://doi.org/10.1158/1538-7445.am2013-2397" @default.
• W2065564927 hasPublicationYear "2013" @default.
• W2065564927 type Work @default.
• W2065564927 sameAs 2065564927 @default.
• W2065564927 citedByCount "1" @default.
• W2065564927 countsByYear W20655649272014 @default.
• W2065564927 crossrefType "proceedings-article" @default.
• W2065564927 hasAuthorship W2065564927A5011626141 @default.
• W2065564927 hasAuthorship W2065564927A5022422153 @default.
• W2065564927 hasAuthorship W2065564927A5037872546 @default.
• W2065564927 hasAuthorship W2065564927A5053655884 @default.
• W2065564927 hasAuthorship W2065564927A5056663291 @default.
• W2065564927 hasAuthorship W2065564927A5062084998 @default.
• W2065564927 hasAuthorship W2065564927A5062468425 @default.
• W2065564927 hasAuthorship W2065564927A5068246195 @default.
• W2065564927 hasAuthorship W2065564927A5069803966 @default.
• W2065564927 hasAuthorship W2065564927A5088419677 @default.
• W2065564927 hasConcept C104317684 @default.
• W2065564927 hasConcept C121608353 @default.
• W2065564927 hasConcept C126322002 @default.
• W2065564927 hasConcept C143998085 @default.
• W2065564927 hasConcept C190283241 @default.
• W2065564927 hasConcept C2775930923 @default.
• W2065564927 hasConcept C2777506169 @default.
• W2065564927 hasConcept C2777542201 @default.
• W2065564927 hasConcept C2777609662 @default.
• W2065564927 hasConcept C2779438470 @default.
• W2065564927 hasConcept C2780110267 @default.
• W2065564927 hasConcept C2780258809 @default.
• W2065564927 hasConcept C2781187634 @default.
• W2065564927 hasConcept C2781197716 @default.
• W2065564927 hasConcept C30481170 @default.
• W2065564927 hasConcept C502942594 @default.
• W2065564927 hasConcept C526805850 @default.
• W2065564927 hasConcept C530470458 @default.
• W2065564927 hasConcept C55493867 @default.
• W2065564927 hasConcept C71924100 @default.
• W2065564927 hasConcept C86554907 @default.
• W2065564927 hasConcept C86803240 @default.
• W2065564927 hasConceptScore W2065564927C104317684 @default.
• W2065564927 hasConceptScore W2065564927C121608353 @default.
• W2065564927 hasConceptScore W2065564927C126322002 @default.
• W2065564927 hasConceptScore W2065564927C143998085 @default.
• W2065564927 hasConceptScore W2065564927C190283241 @default.
• W2065564927 hasConceptScore W2065564927C2775930923 @default.
• W2065564927 hasConceptScore W2065564927C2777506169 @default.
• W2065564927 hasConceptScore W2065564927C2777542201 @default.
• W2065564927 hasConceptScore W2065564927C2777609662 @default.
• W2065564927 hasConceptScore W2065564927C2779438470 @default.
• W2065564927 hasConceptScore W2065564927C2780110267 @default.
• W2065564927 hasConceptScore W2065564927C2780258809 @default.
• W2065564927 hasConceptScore W2065564927C2781187634 @default.
• W2065564927 hasConceptScore W2065564927C2781197716 @default.
• W2065564927 hasConceptScore W2065564927C30481170 @default.
• W2065564927 hasConceptScore W2065564927C502942594 @default.
• W2065564927 hasConceptScore W2065564927C526805850 @default.
• W2065564927 hasConceptScore W2065564927C530470458 @default.
• W2065564927 hasConceptScore W2065564927C55493867 @default.
• W2065564927 hasConceptScore W2065564927C71924100 @default.
• W2065564927 hasConceptScore W2065564927C86554907 @default.
• W2065564927 hasConceptScore W2065564927C86803240 @default.
• W2065564927 hasLocation W20655649271 @default.
• W2065564927 hasOpenAccess W2065564927 @default.
• W2065564927 hasPrimaryLocation W20655649271 @default.
• W2065564927 hasRelatedWork W1606532636 @default.
• W2065564927 hasRelatedWork W2018922262 @default.
• W2065564927 hasRelatedWork W2051444430 @default.
• W2065564927 hasRelatedWork W2067635558 @default.
• W2065564927 hasRelatedWork W2092063599 @default.
• W2065564927 hasRelatedWork W2314878081 @default.
• W2065564927 hasRelatedWork W2318194385 @default.
• W2065564927 hasRelatedWork W2397627572 @default.
• W2065564927 hasRelatedWork W2497487097 @default.
• W2065564927 hasRelatedWork W2525555618 @default.
• W2065564927 hasRelatedWork W2593777781 @default.
• W2065564927 hasRelatedWork W2655216406 @default.
• W2065564927 hasRelatedWork W2762863917 @default.
• W2065564927 hasRelatedWork W2773935447 @default.
• W2065564927 hasRelatedWork W2793173935 @default.
• W2065564927 hasRelatedWork W2927636949 @default.
• W2065564927 hasRelatedWork W3030730675 @default.
• W2065564927 hasRelatedWork W3127056995 @default.
• W2065564927 hasRelatedWork W3207279546 @default.
• W2065564927 hasRelatedWork W416320400 @default.
• W2065564927 isParatext "false" @default.

• next